The Applicant’s descriptive results across various FACT-B measures (subscale and total scores) and EQ-5D measures (health state and index) mostly showed a marked decrease in average scores on the neratinib arm (favoring placebo) compared to the placebo arm in the first month before leveling out to smaller differences between arms from month 3 on. This can possibly be attributed to treatment toxicity and the imbalance in early dropouts that was previously noted.